Back

The MIR-NAT MAPT-AS1 does not regulate Tau expression in human neurons

Policarpo, R.; Wolfs, L.; Martinez-Montero, S.; Vandermeulen, L.; Royaux, I.; Van Peer, G.; Mestdagh, P.; Sierksma, A.; De Strooper, B.; d'Ydewalle, C.

2023-01-27 neuroscience
10.1101/2023.01.27.525631 bioRxiv
Show abstract

The MAPT gene encodes Tau protein, a member of the large family of microtubule-associated proteins. Tau forms large insoluble aggregates that are toxic to neurons in several neurological disorders and neurofibrillary Tau tangles represent a key pathological hallmark of Alzheimers disease (AD) and other tauopathies1,2. Several Tau-lowering strategies are being investigated as a potential treatment for AD but the mechanisms that regulate Tau expression at the transcriptional or translational level are not well understood3,4. Recently, Simone et al.5 reported the discovery of a new type of natural antisense transcripts called MIR-NATs (referring to Mammalian-wide Interspersed Repeats - Natural Antisense Transcripts). Simone and colleagues used MAPT-AS1, a MIR-NAT associated to the MAPT gene as an archetype of this new class of long non-coding RNAs. According to Simone et al., MAPT-AS1 represses Tau translation by competing for ribosomal RNA. We investigated the potential functions of MAPT-AS1 in neurons using the same gain- and loss-of-function experiments as described in the original report and expanded our analysis with complementary approaches. Our data do not support a role for MAPT-AS1 in regulating Tau expression in human neurons and urge to cautiously interpret the data provided by Simone et al.5.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.